These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 24394493

  • 1. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R.
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW.
    Cancer; 2002 Apr 15; 94(8):2224-31. PubMed ID: 12001121
    [Abstract] [Full Text] [Related]

  • 3. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep 15; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 4. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    J Clin Oncol; 2001 May 15; 19(10):2638-46. PubMed ID: 11352955
    [Abstract] [Full Text] [Related]

  • 5. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H.
    Semin Oncol; 2002 Feb 15; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [Abstract] [Full Text] [Related]

  • 6. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.
    Eur J Cancer; 2016 Feb 15; 54():69-74. PubMed ID: 26724422
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF.
    J Clin Oncol; 2000 Sep 15; 18(17):3068-77. PubMed ID: 11001674
    [Abstract] [Full Text] [Related]

  • 8. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S, VESPER Trial Investigators.
    Eur Urol; 2021 Feb 15; 79(2):214-221. PubMed ID: 32868138
    [Abstract] [Full Text] [Related]

  • 9. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma.
    Witjes JA, Wullink M, Oosterhof GO, de Mulder P.
    Eur Urol; 1997 Feb 15; 31(4):414-9. PubMed ID: 9187900
    [Abstract] [Full Text] [Related]

  • 10. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
    von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M.
    J Clin Oncol; 2005 Jul 20; 23(21):4602-8. PubMed ID: 16034041
    [Abstract] [Full Text] [Related]

  • 11. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
    Maeda T, Takahashi A, Hirobe M, Honma I, Masumori N, Itoh N, Tsukamoto T.
    Hinyokika Kiyo; 2007 Apr 20; 53(4):213-9. PubMed ID: 17515069
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
    Cancer; 2015 Aug 01; 121(15):2586-93. PubMed ID: 25872978
    [Abstract] [Full Text] [Related]

  • 13. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikcevich DA, Kugler JW, Rowland KM, Kardinal CG, Wos EJ.
    Gynecol Oncol; 2006 Mar 01; 100(3):501-5. PubMed ID: 16185755
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    J Clin Oncol; 2004 Jan 15; 22(2):220-8. PubMed ID: 14665607
    [Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS.
    Anticancer Res; 2001 Jan 15; 21(1B):711-5. PubMed ID: 11299831
    [Abstract] [Full Text] [Related]

  • 16. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
    Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar 15; 100(3):537-43. PubMed ID: 16216315
    [Abstract] [Full Text] [Related]

  • 17. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
    Roberts JT, von der Maase H, Sengeløv L, Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M.
    Ann Oncol; 2006 May 15; 17 Suppl 5():v118-22. PubMed ID: 16807438
    [Abstract] [Full Text] [Related]

  • 18. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct 15; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 19. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
    Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M.
    Urologe A; 2003 Aug 15; 42(8):1074-86. PubMed ID: 14513232
    [Abstract] [Full Text] [Related]

  • 20. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
    Giannatempo P, Alessi A, Miceli R, Raggi D, Farè E, Nicolai N, Serafini G, Padovano B, Piva L, Biasoni D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Mariani L, Gianni AM, Sonpavde G, Salvioni R, Necchi A, Crippa F.
    Clin Genitourin Cancer; 2014 Dec 15; 12(6):433-9. PubMed ID: 24787972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.